Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
A phase 2 trial of Visugromab, Nivolumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting.
Overview
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC is a phase 2 interventional study registered as NCT07246863 by CatalYm GmbH, with 131 participants planned, started 2025-10-07 and due to reach its primary completion in 2029-10-01. Interventions recorded: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel. Conditions listed: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTrial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Shares Visugromab, CatalYm, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialFirst-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
Shares Visugromab, CatalYm, Nivolumab.
- TrialVisugromab in Cachexia International Trial
Shares Visugromab, CatalYm.
- TrialVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)
Shares Visugromab, CatalYm, Nivolumab.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Docetaxel, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.